Literature DB >> 30378688

Cell-specific Retention and Action of Pheophorbide-based Photosensitizers in Human Lung Cancer Cells.

Erin C Tracy1, Mary-Jo Bowman1, Ravendra K Pandey2, Heinz Baumann1.   

Abstract

This study determined in primary cultures of human lung cancer cells the cell specificity of chlorin-based photosensitizers. Epithelial cells (ECs) preferentially retained 3-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) and related structural variants. Tumor-associated fibroblasts (Fb) differ from EC by a higher efflux rate of HPPH. Immunoblot analyses indicated dimerization of STAT3 as a reliable biomarker of the photoreaction. Compared to mitochondria/ER-localized photoreaction by HPPH, the photoreaction by lysosomally targeted HPPH-lactose showed a trend toward lower STAT3 cross-linking. Lethal consequence of the photoreaction differed between EC and Fb with the latter cells being more resistant. A survey of lung tumor cases indicated a large quantitative range by which EC retains HPPH. The specificity of HPPH retention defined in vitro could be confirmed in vivo in selected cases grown as xenografts. HPPH retention as a function of the tetrapyrrole structure was evaluated by altering side groups on the porphyrin macrocycle. The presence or absence of a carboxylic acid at position 172 proved to be critical. A benzyl group at position 20 enhanced retention in a subset of cancer cells with low HPPH binding. This study indicated experimental tools that are potentially effective in defining the photosensitizer preference and application for individual patient's cancer lesions.
© 2018 The American Society of Photobiology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30378688      PMCID: PMC6496943          DOI: 10.1111/php.13043

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  37 in total

1.  ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy.

Authors:  Robert W Robey; Kenneth Steadman; Orsolya Polgar; Susan E Bates
Journal:  Cancer Biol Ther       Date:  2005-02-08       Impact factor: 4.742

2.  Effect of chirality on cellular uptake, imaging and photodynamic therapy of photosensitizers derived from chlorophyll-a.

Authors:  Avinash Srivatsan; Paula Pera; Penny Joshi; Yanfang Wang; Joseph R Missert; Erin C Tracy; Walter A Tabaczynski; Rutao Yao; Munawwar Sajjad; Heinz Baumann; Ravindra K Pandey
Journal:  Bioorg Med Chem       Date:  2015-04-09       Impact factor: 3.641

Review 3.  Cell biology of the asialoglycoprotein receptor system: a model of receptor-mediated endocytosis.

Authors:  P P Breitfeld; C F Simmons; G J Strous; H J Geuze; A L Schwartz
Journal:  Int Rev Cytol       Date:  1985

4.  Binding of porphyrins to serum proteins.

Authors:  J Moan; C Rimington; J F Evensen; A Western
Journal:  Adv Exp Med Biol       Date:  1985       Impact factor: 2.622

5.  Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.

Authors:  David A Bellnier; William R Greco; Gregory M Loewen; Hector Nava; Allan R Oseroff; Ravindra K Pandey; Takaaki Tsuchida; Thomas J Dougherty
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

Review 6.  Temoporfin (Foscan®, 5,10,15,20-tetra(m-hydroxyphenyl)chlorin)--a second-generation photosensitizer.

Authors:  Mathias O Senge; Johan C Brandt
Journal:  Photochem Photobiol       Date:  2011-09-19       Impact factor: 3.421

7.  Singlet oxygen in a cell: spatially dependent lifetimes and quenching rate constants.

Authors:  Marina K Kuimova; Gokhan Yahioglu; Peter R Ogilby
Journal:  J Am Chem Soc       Date:  2009-01-14       Impact factor: 15.419

8.  The localization and photosensitization of modified chlorin photosensitizers in artificial membranes.

Authors:  Shimshon Ben Dror; Irena Bronshtein; Yuval Garini; William G O'Neal; Peter A Jacobi; Benjamin Ehrenberg
Journal:  Photochem Photobiol Sci       Date:  2009-01-05       Impact factor: 3.982

9.  Porphyrin depth in lipid bilayers as determined by iodide and parallax fluorescence quenching methods and its effect on photosensitizing efficiency.

Authors:  Irena Bronshtein; Michal Afri; Hana Weitman; Aryeh A Frimer; Kevin M Smith; Benjamin Ehrenberg
Journal:  Biophys J       Date:  2004-08       Impact factor: 4.033

10.  Interleukin-1α is the major alarmin of lung epithelial cells released during photodynamic therapy to induce inflammatory mediators in fibroblasts.

Authors:  E C Tracy; M J Bowman; B W Henderson; H Baumann
Journal:  Br J Cancer       Date:  2012-09-20       Impact factor: 7.640

View more
  4 in total

1.  Charged groups on pyropheophorbide-based photosensitizers dictate uptake by tumor cells and photodynamic therapy efficacy.

Authors:  Courtney Saenz; Manivannan Ethirajan; Erin C Tracy; Mary-Jo Bowman; Joseph Cacaccio; Tymish Ohulchanskyy; Heinz Baumann; Ravindra K Pandey
Journal:  J Photochem Photobiol B       Date:  2021-12-15       Impact factor: 6.252

2.  Chiral Alkyl Groups at Position 3(1') of Pyropheophorbide-a Specify Uptake and Retention by Tumor Cells and Are Essential for Effective Photodynamic Therapy.

Authors:  Ravindra R Cheruku; Erin C Tracy; Walter Tabaczynski; Joseph R Missert; Heinz Baumann; Ravindra K Pandey
Journal:  J Med Chem       Date:  2021-04-06       Impact factor: 8.039

3.  Synthesis, Tumor Specificity, and Photosensitizing Efficacy of Erlotinib-Conjugated Chlorins and Bacteriochlorins: Identification of a Highly Effective Candidate for Photodynamic Therapy of Cancer.

Authors:  Ravindra R Cheruku; Joseph Cacaccio; Farukh A Durrani; Walter A Tabaczynski; Ramona Watson; Kevin Siters; Joseph R Missert; Erin C Tracy; Mykhaylo Dukh; Khurshid Guru; Richard C Koya; Pawel Kalinski; Heinz Baumann; Ravindra K Pandey
Journal:  J Med Chem       Date:  2021-01-05       Impact factor: 8.039

4.  Tumor Cell-Specific Retention and Photodynamic Action of Erlotinib-Pyropheophorbide Conjugates.

Authors:  Erin C Tracy; Ravindra R Cheruku; Ravindra K Pandey; Heinz Baumann
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.